Emerging drugs for coronary restenosis: The role of systemic oral agents the in stent era

Expert Opinion on Emerging Drugs

Volumn 14, Issue 4, 2009, Pages 561-576

  Rodriguez, Alfredo E ^a  

^a Sanatorio Otamendi y Miroli   (Argentina)

Author keywords

Angioplasty; Bare metal stents; Drug eluting stents; Restenosis; Sirolimus; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CILOSTAZOL; CLOPIDOGREL; CORTISONE; DILTIAZEM; ESOMEPRAZOLE; EVEROLIMUS; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PIOGLITAZONE; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; RAPAMYCIN; ROSIGLITAZONE; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

ANGIONEUROTIC EDEMA; ARTERY INTIMA PROLIFERATION; BARE METAL STENT; CLINICAL TRIAL; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; HEADACHE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY CANCER; LEUKOPENIA; LOADING DRUG DOSE; MORTALITY; MOUTH PAIN; NANOTECHNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RESTENOSIS; REVIEW; SINUSITIS; SORE GUM; STENOSIS; STENT THROMBOSIS; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; REGISTRIES; SIROLIMUS; STENTS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 71649098608     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903203808     Document Type: Review

References (94)

1. Rodríguez A, Santaera O, Larribau M, et al. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. Am J Cardiol 1993;71:1391-1395
2. Rodríguez A, Palacios I, Fernández M, et al. Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995;76:1131-1134
3. Mintz G, Popma J, Pichard A, et al. Arterial remodeling after coronay angioplasty. A serial intravascular ultrasound study. Circulation 1996;94:35-44
4. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angioplasty: An overview. J Am Coll Cardiol 1991;66:3-6
5. Dimas AP, Grigera F, Arora R, et al. Repeat coronary angioplasty as treatment of restenosis. J Am Coll Cardiol 1992;19:1310-1314
6. Serruys PW, De Jaegere P, Kiemeney F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495
7. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in treatment of coronary artery disease. N Engl J Med 1994;331:496-501
8. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99(16):2164-2170
9. Waksman R, Ajani AE, White RL, et al. Five years follow up after intracoronary gamma radiation therapy for in stent restenosis. Circulation 2000;109:340-347
10. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116(21):2391-2398
11. Popma JJ, Decesare NB, Ellis SG, et al. Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy. Circulation 1991;84:644-653
12. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993;329:221-227
13. Stankovic G, Colombo A, Bersin R, et al. Comparison of directional coronary atherectomy and stenting versus stenting alone for the treatment of de novo and restenotic coronary artery narrowing. Am J Cardiol 2004;93(8):953-958
14. Al Suwaidi J, Holmes DR, Salam AM, et al. Impact of coronary artery stents on mortality and nonfatal myocardial infaction: meta-analysis of randomized trials comparing strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004;147:815-822
15. Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: A meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008;118(11):1146-1154
16. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373(9670):1190-1197
17. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011
18. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularitation. N Eng J Med 2002;346:1773-1780
19. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323
20. Grube E, Silber S, Hauptmann KE, et al. TAXUS I. Six- and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42
21. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794
22. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Eng J Med 2007;356:989-997
23. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008;118:1138-1145
24. Vorpahl M, Nakazawa G, Kolodgie F, Virmani R. Stent related death rates are higher in drug eluting stents than bare metal stents: An autopsy study. Euro PCR 2009;1:abstract -E 118
25. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we cautious? Circulation 2004;109:701-705
26. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-236 (Pubitemid 40966848)
27. Finn AV, Joner M, Nakasawa G, et al. Pathological correlates of late drug eluting stents thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007;115:2435-2441
28. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after DES implantation: An intravascular ultrasound analysis with long term follow up. Circulation 2006;113:414-419
29. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents angioscopic findings. J Am Coll Cardiol 2006;47:2108-2111
30. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007;49:15-20
31. MacFadden EP, Stabile E, Regar E, et al. Late stent trombosis in drug-eluting coronary stent after discontinuation of antiplatelet therapy. Lancet 2004;364:1419-1421
32. Rodríguez AE, Mieres J, Fernández-Pereira C, et al. Coronary stent trombosis in drug-eluting stent era: Insights from ERACI III trial. J Am Coll Cardiol 2006;47:205-207
33. Rodriguez A, Rodriguez-Granillo G, Palacios I. Late stent thrombosis the damocles sword of drug eluting stents. Euro Intervention 2007;2:512-517
34. Versaci F, Gaspardone A, Fabrizio E, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-1942
35. Ribichini F, Tomai F, Ferrero V, et al. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. EuroIntervention 2005;2:173-180
36. Ferrero V, Tomai F, Versaci F, et al. Long term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. Euro Intervention 2009;5:250-254
37. Rodriguez AE, Alemparte MR, Vigo CF, et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina single-center study (ORAR Trial). J Invasive Cardiol 2003;15(10):581-584
38. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The prospective randomized oral rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006;47(8):1522-1529
39. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110(7):790-795
40. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44(7):1386-1392
41. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98(10):2277-2283
42. Farb A, Jhon M, Acampado E, et al. Oral Everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384
43. Dong-Woon K, Jin-Sook K, Young-Gyu K, et al. Novel oral formulation of Paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004;109:1558-1563
44. Deepak L, Bhatt MD, Keith AA, et al.; for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
45. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual non responsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-739
46. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: The Clopidogrel Medco Outcomes Study. Society for Cardiovascular Angiography and Interventions (SCAI) 2009 Scientific Sessions
47. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278
48. Finn AV, Nakazawa G, Kolodgie F, Virmani R. Temporal course of neointimal formation after drug-eluting stent placement: I our understanding of restenosis changing? J Am Coll Cardiol Intv 2009;2:300-302
49. Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008;72(2):237-247
50. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: Three-dimensional ultrasound results of the Diabetes and sirolimus-eluting stent (Diabetes) trial. J Am Coll Cardiol 2006;47(11):2172-2179
51. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents a cause for concern. Circulation 2007;115:1440-1455
52. Grube E, Dawkins K, Guagliumi G, et al. TAXUS VI final 5-year results: A multicentre, randomized trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009;4(5):572-577
53. Holmes DR Jr, Teirstein PS, Satler L, et al. 3-Year follow-up of the SISR (sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis) Trial. J Am Coll Cardiol Interv 2008;1:439-448
54. Rodríguez AE, Waksman R. Sirolimus-eluting stents or vascular brachytherapy for in-stent restenosis after 3-year follow-up of the SISR (Sirolimus-eluting stent versus vascular brachytherapy for in-stent restenosis) Trial: A call for caution? J Am Coll Cardiol Intv 2009;2:75-76
55. Van Der Hoeven BL, Liem SS, Dijkstra J, et al. Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: Acute and 9-month intravascular ultrasound results of the MISSION! Intervention study. J Am Coll Cardiol Intv 2008;1(2):192-201
56. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-2434
57. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): A randomized non-inferiority trial. Lancet 2008;372(9644):1163-1173
58. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple Imaging methods. Lancet 2009;373(9667):897-910
59. Serruys PW, Ong ATL, Piej JJ, et al. A randomized comparison of a durable polymer everolimus-eluting coronary stent with a bare metal coronary stent. EuroIntervention 2006;2:286-294
60. Fajadet J, Wins W, Laarman GJ, et al. Randomized, double blind, multicenter study of the Endeavor zotarolimus phosporilcoline encapsulated stent for the treatment of native coronary lesions: Clinical and Angiographic Results from the ENDEAVOR II Trial. Minerva Cardioangiol 2007;55:1-18
61. Tardiff JC, Gregoire J, Lallier PL. Prevention of restenosis with antioxidants: mechanism and implications. Am J Cardiovasc Drugs 2002;2(5):323-334
62. Serruys PW, Pim de Feyter, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287(24):3215-3222
63. Douglas JS, Holmes DR Jr, Kereiakes DJ. Coronary stent restenosis in patient treated with cilostazol. Cilostazol for restenosis trial (CREST) Investigators. Circulation 2005;112(18):2826-2832
64. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTENCE (Adjuntive Cilostazol Versus High Maintenance Dose Clopidogrel in Patient With Clopidogrel Resistence) randomized study. J Am Coll Cardiol 2009;53(13):1101-1109
65. Vezina C, Kudelski A, Sehgal SN. Rapamicyn (AY-22,989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-726
66. Ge J, Shen C, Liang C, et al. Elevated matrix metalloproteinase expression after stent implatantation is associated with restenosis. Int J Cardiol 2006;112(1):85-90
67. Marx SO, Marks AR. Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855
68. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22(11):1769-1776
69. Jones GT, Kay IP, Chu JW, et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006;26(7):e121-5
70. Brito FS Jr, Rosa WC, Arruda JA, et al. Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia. Catheter Cardiovasc Interv 2005;64(4):413-418
71. Rodríguez A, Maree A, Tarragona S, et al. Percutaneous coronary interventions with oral sirolimus plus bare metal stents has comparable efficacy and safety to treatment with drug eluting stents, but with significant cost saving: long term follow up results from the randomized, controlled ORAR III Study. EuroIntervention 2009;5:255-264
72. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297(18):1992-2000
73. Win HK, Caldera AE, Maresh K, et al.; for the EVENT registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297(18):2001-2009
74. Jhon M, Acampado E, et al. Oral Everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384
75. Dong-Woon K, Jin-Sook K, Young-Gyu K, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004;109:1558-1563
76. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Euro Intervention 2006;2:286-294
77. Westedt U, Kalinowski M, Wittmar M, et al. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J Control Release 2007;119(1):41-51
78. Elford HL, Cardounel AJ. 20080050414; 2008
79. Rodríguez AE, Maree AO, Mieres J, et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 2007;28(17):2118-2125
80. Morice MC, Colombo A, Meier B, et al. Sirolimus vs paclitaxel eluting stents in de novo coronary artery lesions: The REALITY Trial A Randomized Controlled trial. JAMA 2006;295:895-904
81. Serruys PW, Daemen J, Morice MC, et al. Three years follow up of the ARTS-II-sirolimus eluting stents for the treatment of patients withmultivessel coronary artery disease. Euro Intervention 2008;3:450-459
82. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 2005;293:2126-2130
83. Rodríguez AE, Fernandez-Pereira C. Systemic immunosuppressive therapy with oral sirolimus after bare metal stent implantation: The missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Rec Patents Cardiovasc Drug Discov 2008;3(3):201-208
84. The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007;49:1600-1606
85. Daemen J, Ong AT, Stefanini GG, et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 2006;98(7):895-901
86. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-508
87. Takagi T, Okura H, Kobayashi Y, et al. A prospective, multicenter, randomized Trial to assess efficacy of pioglitazone of in stent neointimal suppression in type 2 diabetics. J Am Coll Cardiol Intv 2009;2:524-531
88. Yang J. WO080085293; 2008
89. Kholodgi FD, John M, Khurana C, et al. Sustained reduction of in stent neointimal growth with the use of the novel systemic nanoparticle of paclitaxel. Circulation 2002;106:1195-1198
90. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355(20):2113-2124
91. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591
92. James SK, Stenestrand U, Lindbäck J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933-1945
93. ClinicalTrials.gov; 2009
94. The BARI 2 Study Group. Randomized Trial of Therapies From Type 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009;360:2503-2515